Internship

Chemical Process Development

Posted on 10/11/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

No H1B Sponsorship

Franklin Township, NJ, USA

Interns residing more than 50 miles away from New Brunswick, NJ will receive a housing stipend.

Category
Lab & Research
Life Sciences
Requirements
  • Candidates must be currently enrolled in an accredited university program seeking a Ph.D. in Chemistry.
  • Must include resume with GPA (3.0 or greater) and a two-page research summary for consideration.
  • Must have good oral/written communication skills and be able to work in a team environment.
  • Candidates must be a US citizen, have a lawful permanent resident of the US or otherwise authorized to work in the US without requiring sponsorship at this time.
Responsibilities
  • Work with mentors for ~10 weeks on a guided research project within a CPD Project Team.
  • Gain valuable industry and functional experience.
  • Work on challenging assignments.
  • Learn about BMS and meet diverse company representatives.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and cardiovascular conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality and safety standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's AI-driven R&D enhances drug discovery and development efficiency.
  • The $3.5bn agreement with Prime Medicine boosts BMS's cell and gene-therapy pipeline.
  • BMS's commitment to ESG initiatives aligns with industry sustainability trends.

What critics are saying

  • Lawsuits against HRSA and HHS could lead to regulatory and financial challenges.
  • The $6.4 billion lawsuit by UMB poses potential financial liabilities for BMS.
  • The collaboration with AI Proteins may not yield viable therapeutic candidates.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE